# A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis

> **NCT06406205** · PHASE3 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 270 (estimated)

## Conditions studied

- Lupus Nephritis

## Interventions

- **DRUG:** Voclosporin（QL1074）
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06406205
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-25
- **Primary completion:** 2027-06
- **Final completion:** 2028-06
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2024-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06406205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06406205, "A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06406205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*